Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 438.44 Thousand USD | 112.59% |
| 2021 | -3.48 Million USD | -160.96% |
| 2020 | -1.33 Million USD | -6249.89% |
| 2019 | 21.69 Thousand USD | 100.69% |
| 2018 | -3.15 Million USD | -41.13% |
| 2017 | -2.23 Million USD | -103.73% |
| 2016 | 60.05 Million USD | 11.4% |
| 2015 | 53.91 Million USD | 89.54% |
| 2014 | 28.44 Million USD | 639.65% |
| 2013 | -5.27 Million USD | -1027.52% |
| 2012 | 568.26 Thousand USD | 102.56% |
| 2011 | -22.18 Million USD | -248.88% |
| 2010 | -6.35 Million USD | -219.83% |
| 2009 | 5.3 Million USD | 111.0% |
| 2008 | 2.51 Million USD | -35.61% |
| 2007 | 3.9 Million USD | -7.56% |
| 2006 | 4.22 Million USD | 228.94% |
| 2005 | 1.28 Million USD | 131.6% |
| 2004 | -4.06 Million USD | -347.63% |
| 2003 | -907.94 Thousand USD | -78.68% |
| 2002 | -508.13 Thousand USD | 87.58% |
| 2001 | -4.09 Million USD | 8.93% |
| 2000 | -4.49 Million USD | -1196.67% |
| 1999 | -346.55 Thousand USD | 77.75% |
| 1998 | -1.55 Million USD | 79.22% |
| 1997 | -7.49 Million USD | 74.1% |
| 1996 | -28.92 Million USD | -240.33% |
| 1995 | -8.5 Million USD | -1.19% |
| 1994 | -8.4 Million USD | -740.0% |
| 1993 | -1 Million USD | 88.24% |
| 1992 | -8.5 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | -2.6 Million USD | 45.79% |
| 2023 Q1 | 2.28 Million USD | 421.03% |
| 2023 Q2 | -4.8 Million USD | -310.34% |
| 2022 Q3 | -2.78 Million USD | -642.31% |
| 2022 Q2 | 512.76 Thousand USD | 157.38% |
| 2022 Q1 | -893.7 Thousand USD | 74.33% |
| 2022 FY | 438.44 Thousand USD | 112.59% |
| 2022 Q4 | 438.44 Thousand USD | 115.77% |
| 2021 Q1 | -6.8 Million USD | -409.94% |
| 2021 Q2 | -6.67 Million USD | 1.81% |
| 2021 Q3 | -6.79 Million USD | -1.74% |
| 2021 Q4 | -3.48 Million USD | 48.77% |
| 2021 FY | -3.48 Million USD | -160.96% |
| 2020 Q1 | 356.28 Thousand USD | 1542.4% |
| 2020 Q3 | -2.69 Million USD | -443.51% |
| 2020 FY | -1.33 Million USD | -6249.89% |
| 2020 Q4 | -1.33 Million USD | 50.42% |
| 2020 Q2 | -495.05 Thousand USD | -238.95% |
| 2019 Q3 | -2.01 Million USD | 53.3% |
| 2019 Q1 | -343.67 Thousand USD | 89.12% |
| 2019 Q2 | -4.31 Million USD | -1156.52% |
| 2019 FY | 21.69 Thousand USD | 100.69% |
| 2019 Q4 | 21.69 Thousand USD | 101.08% |
| 2018 Q4 | -3.15 Million USD | -7.52% |
| 2018 FY | -3.15 Million USD | -41.13% |
| 2018 Q1 | 2.14 Million USD | 195.73% |
| 2018 Q2 | -1.87 Million USD | -187.31% |
| 2018 Q3 | -2.93 Million USD | -57.05% |
| 2017 Q2 | -3.63 Million USD | 67.93% |
| 2017 Q1 | -11.33 Million USD | -118.88% |
| 2017 Q4 | -2.23 Million USD | 15.13% |
| 2017 Q3 | -2.63 Million USD | 27.46% |
| 2017 FY | -2.23 Million USD | -103.73% |
| 2016 Q2 | 60.01 Million USD | 8.4% |
| 2016 Q1 | 55.36 Million USD | 2.7% |
| 2016 Q4 | 60.05 Million USD | -2.17% |
| 2016 Q3 | 61.39 Million USD | 2.29% |
| 2016 FY | 60.05 Million USD | 11.4% |
| 2015 Q4 | 53.91 Million USD | 8.02% |
| 2015 Q1 | 30.51 Million USD | 7.28% |
| 2015 FY | 53.91 Million USD | 89.54% |
| 2015 Q2 | 43.37 Million USD | 42.16% |
| 2015 Q3 | 49.9 Million USD | 15.05% |
| 2014 Q1 | 4.93 Million USD | 193.58% |
| 2014 FY | 28.44 Million USD | 639.65% |
| 2014 Q2 | 13.74 Million USD | 178.75% |
| 2014 Q4 | 28.44 Million USD | 28.74% |
| 2014 Q3 | 22.09 Million USD | 60.68% |
| 2013 Q2 | 1.66 Million USD | -47.28% |
| 2013 Q3 | -16.85 Million USD | -1110.31% |
| 2013 FY | -5.27 Million USD | -1027.52% |
| 2013 Q4 | -5.27 Million USD | 68.73% |
| 2013 Q1 | 3.16 Million USD | 456.77% |
| 2012 Q3 | -5.19 Million USD | 49.98% |
| 2012 Q1 | -15.39 Million USD | 30.6% |
| 2012 Q4 | 568.26 Thousand USD | 110.95% |
| 2012 FY | 568.26 Thousand USD | 102.56% |
| 2012 Q2 | -10.37 Million USD | 32.58% |
| 2011 Q2 | -7.53 Million USD | 22.06% |
| 2011 Q4 | -22.18 Million USD | 30.17% |
| 2011 FY | -22.18 Million USD | -248.88% |
| 2011 Q1 | -9.66 Million USD | -52.07% |
| 2011 Q3 | -31.76 Million USD | -321.54% |
| 2010 Q1 | 4.99 Million USD | -6.4% |
| 2010 FY | -6.35 Million USD | -219.83% |
| 2010 Q4 | -6.35 Million USD | -145.61% |
| 2010 Q3 | -2.58 Million USD | 33.95% |
| 2010 Q2 | -3.91 Million USD | -178.46% |
| 2009 FY | 5.3 Million USD | 111.0% |
| 2009 Q1 | 2.57 Million USD | 2.35% |
| 2009 Q4 | 5.33 Million USD | 8.45% |
| 2009 Q3 | 4.92 Million USD | 59.19% |
| 2009 Q2 | 3.09 Million USD | 20.11% |
| 2008 Q1 | 3.96 Million USD | 1.52% |
| 2008 Q4 | 2.51 Million USD | -21.05% |
| 2008 Q2 | 2.17 Million USD | -45.04% |
| 2008 FY | 2.51 Million USD | -35.61% |
| 2008 Q3 | 3.18 Million USD | 46.18% |
| 2007 Q4 | 3.9 Million USD | -20.81% |
| 2007 FY | 3.9 Million USD | -7.56% |
| 2007 Q1 | 4.31 Million USD | 2.14% |
| 2007 Q2 | 4.88 Million USD | 13.2% |
| 2007 Q3 | 4.93 Million USD | 0.96% |
| 2006 Q2 | 1.63 Million USD | 159.4% |
| 2006 Q1 | 630.22 Thousand USD | -50.93% |
| 2006 FY | 4.22 Million USD | 228.94% |
| 2006 Q4 | 4.22 Million USD | 51.05% |
| 2006 Q3 | 2.79 Million USD | 71.09% |
| 2005 Q2 | 1.29 Million USD | 215.92% |
| 2005 Q4 | 1.28 Million USD | -45.44% |
| 2005 FY | 1.28 Million USD | 131.6% |
| 2005 Q1 | 408.5 Thousand USD | 110.05% |
| 2005 Q3 | 2.35 Million USD | 82.39% |
| 2004 Q3 | -2.81 Million USD | 12.96% |
| 2004 FY | -4.06 Million USD | -347.63% |
| 2004 Q1 | -3.14 Million USD | -245.97% |
| 2004 Q2 | -3.23 Million USD | -2.87% |
| 2004 Q4 | -4.06 Million USD | -44.52% |
| 2003 FY | -907.94 Thousand USD | -78.68% |
| 2003 Q4 | -907.94 Thousand USD | -9515.6% |
| 2003 Q3 | 9643.00 USD | -85.43% |
| 2003 Q2 | 66.18 Thousand USD | 127.22% |
| 2003 Q1 | -243.15 Thousand USD | 52.15% |
| 2002 Q4 | -508.13 Thousand USD | -293.22% |
| 2002 Q1 | -1.08 Million USD | 73.57% |
| 2002 Q2 | 51.09 Thousand USD | 104.72% |
| 2002 Q3 | 262.98 Thousand USD | 414.71% |
| 2002 FY | -508.13 Thousand USD | 87.58% |
| 2001 Q4 | -4.09 Million USD | 15.23% |
| 2001 Q1 | -3.65 Million USD | 18.61% |
| 2001 FY | -4.09 Million USD | 8.93% |
| 2001 Q2 | -4.41 Million USD | -20.64% |
| 2001 Q3 | -4.82 Million USD | -9.4% |
| 2000 Q3 | -3.22 Million USD | -32.69% |
| 2000 Q1 | -2.39 Million USD | 44.68% |
| 2000 FY | -4.49 Million USD | -1196.67% |
| 2000 Q4 | -4.49 Million USD | -39.39% |
| 2000 Q2 | -2.42 Million USD | -1.43% |
| 1999 Q1 | -2.5 Million USD | -60.52% |
| 1999 Q3 | -4.22 Million USD | -148.24% |
| 1999 Q4 | -4.33 Million USD | -2.61% |
| 1999 FY | -346.55 Thousand USD | 77.75% |
| 1999 Q2 | -1.7 Million USD | 32.0% |
| 1998 Q2 | -800 Thousand USD | 77.78% |
| 1998 FY | -1.55 Million USD | 79.22% |
| 1998 Q4 | -1.55 Million USD | -273.05% |
| 1998 Q1 | -3.6 Million USD | 51.96% |
| 1998 Q3 | 900 Thousand USD | 212.5% |
| 1997 Q2 | -18.5 Million USD | 28.57% |
| 1997 Q3 | -16.2 Million USD | 12.43% |
| 1997 Q4 | -7.49 Million USD | 53.74% |
| 1997 Q1 | -25.9 Million USD | 10.47% |
| 1997 FY | -7.49 Million USD | 74.1% |
| 1996 Q4 | -28.92 Million USD | -13.89% |
| 1996 Q1 | -9 Million USD | -5.88% |
| 1996 Q2 | -28.8 Million USD | -220.0% |
| 1996 Q3 | -25.4 Million USD | 11.81% |
| 1996 FY | -28.92 Million USD | -240.33% |
| 1995 Q2 | -8.9 Million USD | -74.51% |
| 1995 Q4 | -8.5 Million USD | 7.61% |
| 1995 Q1 | -5.1 Million USD | 39.29% |
| 1995 FY | -8.5 Million USD | -1.19% |
| 1995 Q3 | -9.2 Million USD | -3.37% |
| 1994 FY | -8.4 Million USD | -740.0% |
| 1994 Q3 | -100 Thousand USD | 66.67% |
| 1994 Q4 | -8.4 Million USD | -8300.0% |
| 1994 Q2 | -300 Thousand USD | 57.14% |
| 1994 Q1 | -700 Thousand USD | 30.0% |
| 1993 Q4 | -1 Million USD | -100.0% |
| 1993 FY | -1 Million USD | 88.24% |
| 1993 Q1 | -4 Million USD | 52.94% |
| 1993 Q2 | -500 Thousand USD | 87.5% |
| 1993 Q3 | -500 Thousand USD | 0.0% |
| 1992 FY | -8.5 Million USD | 0.0% |
| 1992 Q3 | -100 Thousand USD | 0.0% |
| 1992 Q4 | -8.5 Million USD | -8400.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 108.868% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 111.493% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 99.59% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 100.588% |
| Azitra, Inc. | -910.04 Thousand USD | 148.178% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 110.346% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 62.599% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 91.547% |
| CEL-SCI Corporation | 9.42 Million USD | 95.349% |
| iBio, Inc. | -9.75 Million USD | 104.497% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 101.349% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 106.131% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | 134.227% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | 212.422% |
| NanoViricides, Inc. | -4.79 Million USD | 109.138% |
| Oragenics, Inc. | -3.17 Million USD | 113.828% |
| BiomX Inc. | -772 Thousand USD | 156.793% |
| BiomX Inc. | -772 Thousand USD | 156.793% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 83.436% |
| Palatin Technologies, Inc. | -8.93 Million USD | 104.906% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 96.836% |